Sign in
PFE-PFIZER INC

Pfizer Shows Strong Dividend Performance and Growth Potential Amid Stock Challenges and Market Uncertainty

Monday

02 December, 2024

Despite facing stock challenges and market uncertainty, Pfizer showcases a robust dividend yield of 6.5% and a promising growth trajectory with nine new FDA-approved medications. Can a thriving oncology division and strategic acquisitions turn the tide for this pharmaceutical giant?

article image for PFE

Article Impact Score

0
50
100
Under­perform
Bear­ish
Neu­tral
Bull­ish
Out­perform
66
Key Takeaways
  • Pfizer offers a high dividend yield of around 6.5% and a solid record of dividend growth.
  • The company has achieved nine new FDA approvals in 2023, indicating strong product development.
  • Its oncology sector is performing well, with a notable 31% rise in cancer treatment sales.
  • The recent acquisition of Seagen for $43 billion is expected to boost Pfizer's growth opportunities.
  • Analysts predict significant upside for Pfizer's stock, currently trading below its recent peak.
More on PFIZER INC
Read more insights on PFIZER INC

Most Read

Join Foliko Premium!

Unlock the entire library of Foliko's Generative AI Investment Research. Plus, get AI powered trading signals and stock price predictions.

Go Premium - 7 Day Free Trial
home-footer-logo

Any content provided on our website is for information purposes only. We do not provide investment advice, nor do we consider ourselves a financial institution. Seek a duly licensed professional for investment advice.